Encapsulation of iguratimod (IGU) within poly (lactic-co-glycolic acid) (PLGA) nanoparticles (IGU-PLGA-NPs) triggers apoptosis in MM cells by activating the Caspase-dependent signaling pathway, markedly suppressing the proliferation of CD138-CD34-MM CSCs, and exhibits favorable anti-tumor effects in both in vitro and in vivo experiments [94]. Here, CD34 is linked to Miyoshi myopathy.